We are looking for a research scientist with extensive experience in formulation and characterization of vaccines and biologic drugs to join the Jurata team at our R&D site in Austin, Texas. The successful candidate will be responsible for conducting proof-of concept studies for new payloads/clients. They will also be involved in drafting SOP documents needed for regulatory filings. Strong communication skills are essential, along with excellent organizational skills and the ability to prioritize and manage multiple and diverse projects. Specific duties include:
Design experimental protocols to analyze and characterize formulations and payload stability
Optimize formulations, as needed, for therapeutic payload some of which are Biosafety II agents
Perform In Vivo studies in small animal models
Perform experiments in a timely fashion by agreed-upon deadlines
Report weekly R&D progress to Jurata team.
Serve as technical lead in communications with clients and industry partners
Publish novel research in collaboration with clients/partners in high quality peer-reviewed scientific journals.
Provide support in writing and the preparation of grant applications (NIH, NSF, DOD etc).
PhD required, specialties could include Pharmaceutics, Bioengineering, Biochemistry or other related life sciences
2+ years post-PhD research experience
Demonstrated ability to adapt to diverse interdisciplinary research projects
Superior time management skills and ability to multitask between different research projects
Excellent interpersonal and communication skills
Highly organized and detail-oriented with thorough documentation practices
Demonstrated publication experience
About Jurata Thin Film
Founded in 2019, with headquarters located in the Research Triangle Park area of North Carolina and Research and Development space in Austin, Texas, Jurata Thin Film, Inc. is a privately-held biotechnology company working to revolutionize the way vaccines and biologics are stored, distributed and delivered to all who need them around the world. Jurata’s leading technology, MSI-TX, allows biologics and vaccines embedded within its matrix to be stored at room temperature for extended periods of time while maintaining therapeutic payload potency. MSI-TX has also been proven to protect its cargo even when exposed to extreme temperatures, as is often the case during shipping and distribution. This technology could remove the need for cold chain logistics in vaccine and biologic transport and storage, while exponentially reducing the space required to store these lifesaving therapies.